Day One Biopharmaceuticals Ownership | Who Owns Day One Biopharmaceuticals?

Overview Forecast RevenueFinancials Chart Transcripts

Day One Biopharmaceuticals Ownership Summary

Day One Biopharmaceuticals is owned by 44.66% institutional investors, 16.82% insiders, and 38.52% retail investors. Vanguard group is the largest institutional shareholder, holding 6.08% of DAWN shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.43% of its assets in Day One Biopharmaceuticals shares.

DAWN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Day One Biopharmaceuticals	44.66%	16.82%	38.52%
Sector	Healthcare Stocks	35.56%	12.08%	52.36%
Industry	Biotech Stocks	35.43%	12.01%	52.56%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vanguard group	6.28M	6.08%	$58.55M
Blackrock	4.53M	5.23%	$62.47M
Braidwell lp	2.18M	2.12%	$15.38M
Boxer capital	1.19M	1.37%	$16.40M
J. goldman & co lp	569.62K	0.55%	$4.02M
Janus henderson group	546.43K	0.53%	$11.71M
Jane street group	475.44K	0.46%	$10.19M
Parkwood	275.00K	0.27%	$1.94M
Trexquant investment lp	266.58K	0.26%	$1.88M
Capstone investment advisors	236.00K	0.23%	$5.06M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Boxer capital	1.19M	0.86%	$16.40M
Braidwell lp	2.18M	0.46%	$15.38M
Parkwood	275.00K	0.18%	$1.94M
Pharvision advisers	42.34K	0.17%	$298.53K
Mint tower capital management b.v.	60.00K	0.12%	$1.29M
J. goldman & co lp	569.62K	0.10%	$4.02M
Susquehanna fundamental investments	138.42K	0.04%	$975.86K
Sherbrooke park advisers	11.46K	0.04%	$80.77K
Nebula research & development	60.66K	0.03%	$394.32K
Css llc/il	24.00K	0.02%	$514.56K

Top Buyers

Holder	Shares	% Assets	Change
Janus henderson group	546.43K	0.01%	525.13K
Capstone investment advisors	236.00K	0.01%	236.00K
Norges bank	169.00K	0.00%	169.00K
Trexquant investment lp	266.58K	0.02%	151.15K
Vanguard group	6.28M	0.00%	101.05K

Top Sellers

Holder	Shares	% Assets	Change
Blackrock funding, inc. /de	-	-	-7.04M
Atlas venture life science advisors	-	-	-6.41M
Ra capital management	-	-	-5.76M
Vestal point capital, lp	-	-	-5.20M
Glazer capital	-	-	-4.68M

New Positions

Holder	Shares	% Assets	Change	Value
Norges bank	169.00K	0.00%	169.00K	$1.58M
Mint tower capital management b.v.	60.00K	0.12%	60.00K	$1.29M
Pharvision advisers	42.34K	0.17%	42.34K	$298.53K
Css llc/il	24.00K	0.02%	24.00K	$514.56K
Clear street markets	807.00	0.00%	807.00	$5.69K

Sold Out

Holder	Change
Dunhill financial	-1.00
Freestone grove partners lp	-2.00
Jones financial companies lllp	-2.00
Smartleaf asset management	-5.00
Advisory services network	-11.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	130	-34.34%	46,169,267	-43.29%	44	0.72%	86	-25.86%	28	-39.13%
Dec 31, 2025	159	-7.56%	61,236,176	-28.40%	59	0.86%	91	1.11%	37	-33.93%
Sep 30, 2025	167	-1.76%	83,154,276	1.47%	80	1.28%	87	-12.12%	54	10.20%
Jun 30, 2025	178	-6.32%	86,133,514	0.67%	83	1.20%	101	-6.48%	52	10.64%
Mar 31, 2025	193	11.56%	94,051,909	0.33%	91	0.97%	108	13.68%	47	20.51%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	2.46M	2.43%	522.40K
Vanguard Total Stock Mkt Idx Inv	2.46M	2.38%	48.47K
Polar Capital Biotech S Inc	2.11M	2.06%	-
iShares Russell 2000 ETF	1.90M	1.84%	-15.51K
Pictet-Biotech P USD	1.69M	1.64%	1.69M
Franklin US Small Cap Growth Equity	1.61M	1.59%	130.60K
Franklin Small Cap Growth SMA	1.61M	1.59%	1.61M
Franklin Biotechnology Discv A(acc)USD	1.55M	1.52%	-
Franklin Small Cap Growth Adv	1.48M	1.45%	-
Pictet Biotech	1.37M	1.40%	1.37M

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 17, 2026	Merendino Lauren	Chief Commercial Officer	Sell	$67.45K
Feb 17, 2026	Dubow Adam	Gen Counsel & Secretary	Sell	$74.19K
Feb 17, 2026	York Charles N II	COO and CFO	Sell	$70.36K
Feb 17, 2026	Bender Jeremy	CHIEF EXECUTIVE OFFICER	Sell	$179.34K
Feb 17, 2026	VASCONCELLES MICHAEL	Head of Research and Dev.	Sell	$31.65K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	-
2026 Q1	-	5
2025 Q4	-	4
2025 Q3	-	4
2025 Q2	-	4

DAWN Ownership FAQ

Who Owns Day One Biopharmaceuticals?

Day One Biopharmaceuticals shareholders are primarily institutional investors at 44.66%, followed by 16.82% insiders and 38.52% retail investors. The average institutional ownership in Day One Biopharmaceuticals's industry, Biotech Stocks , is 35.43%, which Day One Biopharmaceuticals exceeds.

Who owns the most shares of Day One Biopharmaceuticals?

Day One Biopharmaceuticals’s largest shareholders are Vanguard group (6.28M shares, 6.08%), Blackrock (4.53M shares, 5.23%), and Braidwell lp (2.18M shares, 2.12%). Together, they hold 13.42% of Day One Biopharmaceuticals’s total shares outstanding.

Does Blackrock own Day One Biopharmaceuticals?

Yes, BlackRock owns 5.23% of Day One Biopharmaceuticals, totaling 4.53M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 62.47M$. In the last quarter, BlackRock decreased its holdings by -498K shares, a -9.90% change.

Who is Day One Biopharmaceuticals’s biggest shareholder by percentage of total assets invested?

Boxer capital is Day One Biopharmaceuticals’s biggest shareholder by percentage of total assets invested, with 0.86% of its assets in 1.19M Day One Biopharmaceuticals shares, valued at 16.4M$.

Who is the top mutual fund holder of Day One Biopharmaceuticals shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Day One Biopharmaceuticals shares, with 2.43% of its total shares outstanding invested in 2.46M Day One Biopharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools